Javascript is required for the SCS calendar.

Globus Medical will acquire Nevro in an all-cash transaction. Both company boards of directors have unanimously approved the ...

Nevro (NYSE:NVRO – Get Free Report) was upgraded by research analysts at Jefferies Financial Group from an “underperform” rating to a “hold” rating in a research note issued to investors on Monday, ...

Globus Medical GMED has entered into a definitive agreement to acquire Nevro Corp. NVRO in an all-cash transaction valued at approximately $250 million. Under the terms of the agreement, unanimously ...

GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

Fintel reports that on February 7, 2025, Piper Sandler upgraded their outlook for Nevro (NYSE:NVRO) from Underweight to Neutral. Analyst Price Forecast Suggests 37.44% Upside As of January 28, 2025, ...

Jefferies upgraded Nevro (NVRO) to Hold from Underperform with a price target of $5.85, up from $4.50, after the company entered into a definitive agreement for Globus Medical to acquire all its ...

Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the ...